EGFR mutation status of the patients with clinical correlation.

<p>EGFR mutation status of the patients with clinical correlation.</p

Patient Demographics.

<p>Patient Demographics.</p

Frequency and Overall mutation rate of different variables in NSCLC.

<p>Frequency and Overall mutation rate of different variables in NSCLC.</p

Toxicities.

<p>Toxicities.</p

Patient demographics, clinical characteristics and details of EGFR mutation.

<p>Patient demographics, clinical characteristics and details of EGFR mutation.</p

Survival by <i>EGFR</i> mutation status.

<p>(A) Progression-free survival (PFS) for the <i>EGFR</i> mutant patients was 10 months (95% CI: 8–11.9 months), while the estimated median PFS for <i>EGFR</i> mutation negative patients was 2 months (95% CI: 1.5–2.5 months), p = 0.000 by log rank test (Mantel Cox). (B) Overall survival (OS) for <i>EGFR</i> mutant patients was 21 months (95% CI: 12.4–25.6 months), while the estimated median OS for <i>EGFR</i> mutantion negative patients was 10 months (95% CI: 7.4–12.6 months), p = 0.001 by log rank test (Mantel Cox).</p

<i>EGFR</i> (exon 18–21) mutation status among NSCLC patients in India.

<p>(A) <i>EGFR</i> mutation status across all NSCLC samples is shown. Black segment in the inner circle indicate patients harboring <i>EGFR</i> mutation, the segment in white indicates patients with wild type <i>EGFR</i>. The segment in grey (outer circle) indicates total number of NSCLC patients. (B) <i>EGFR</i> mutations across different histological subtypes. Grey segment in the outer circle indicate total number of lung adenocarcinoma patients. The patients with squamous histology are represented in dark grey. The segment in white represents lung cancer patients with tumors histology other than adeno or squamous carcinoma. Similar to (A), the black segment in the inner circle indicate patients harboring <i>EGFR</i> mutation, the segment in white indicates patients with wild type <i>EGFR</i>.(C) <i>EGFR</i> mutation variation among male and female lung adenocarcinoma patients. The light grey slice represents male patients; female lung adenocarcinoma patients represented in dark grey in outer circle. Similar to (A), the black segment in the inner circle indicate patients harboring <i>EGFR</i> mutation, the segment in white indicates patients with wild type <i>EGFR</i> among male and female lung adenocarcinoma patients. (D) <i>EGFR</i> mutation variation with respect to gender specific smoking habits among all lung adenocarcinoma patients. Light grey segment in the outer circle indicate male adenocarcinoma lung cancer patients with smoking history. The non smoker male and female lung adenocarcinoma patients are represented in dark grey and white, respectively. The segment in white represents lung cancer patients with tumors histology other than adeno or squamous carcinoma.</p

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country

<div><p>Objectives</p><p>To evaluate the performance and treatment profile of advanced EML4—ALK positive Non-small cell lung cancer (NSCLC) patients in a developing country with potentially restricted access to Crizotinib.</p><p>Materials and Methods</p><p>A retrospective analysis of advanced ALK positive NSCLC patients who were treated from June 2012 to September 2015 was conducted. The primary goal was to evaluate outcomes of advanced ALK positive NSCLC in our practice and examine the logistic constraints in procuring Crizotinib.</p><p>Results</p><p>94 patients were available for analysis. 21 (22.3%) patients were started on Crizotinib upfront, 60 (63.8%) on chemotherapy, 10 (10.6%) on Tyrosine kinase inhibitors (in view of poor PS) and 3 (3.2%) patients were offered best supportive care. Reasons for not starting Crizotinib upfront included symptomatic patients needing early initiation of therapy (23.3%), ALK not tested upfront (23.3%) and financial constraints (21.9%). 69 patients (73.4%) received Crizotinib at some stage during treatment. Dose interruptions (> 1 week) with Crizotinib were seen in 20 patients (29%), with drug toxicity being the commonest reason (85%). Median Progression free survival (PFS) on first line therapy for the entire cohort was 10 months, with a significant difference between patients receiving Crizotinib and those who did not ever receive Crizotinib (10 months vs. 2 months, p = 0.028). Median Overall Survival (OS) was not reached for the entire cohort, with 1 year survival being 81.2%. Patients with an ECOG Performance Status (PS) of >2 had a significantly reduced PFS compared to patients with PS < = 2 (1.5 months vs. 11 months, p< 0.001). 47 patients with financial constraints (68.1%) received Crizotinib completely free via various extramural support schemes.</p><p>Conclusion</p><p>A majority of our ALK positive NSCLC patients were exposed to Crizotinib through the help of various support mechanisms and these patients had similar outcomes to that reported from previously published literature.</p></div

Progression Free Survival as per exposure to Crizotinib.

<p>Progression Free Survival as per exposure to Crizotinib.</p

Overall Survival as per exposure to Crizotinib.

<p>Overall Survival as per exposure to Crizotinib.</p